PRESENT: See enclosed attendance record.

1. **Call to order**: Dr. Williams called the meeting to order at 1:14 pm.

2. **Set date/time of next meeting**: The next meeting is scheduled for December 04, 2009 from 1-3PM; RHCY AB Conference Room.

3. **Minutes**: The minutes of the October 2009 PMAC meeting were reviewed and approved with the following change: The year in the date of the next seminar; change from 2009 to 2010.

4. **Announcements**:
   - Sub-committee on Obesity update: the first meeting is scheduled for today at 3pm. A protocol or flow sheet will be developed to describe actions to be taken when children on psychotropic medications are gaining weight.
     - Committee Membership: Dr. Siegel (Chair), Aurele Kamm, Kristine Ridyard, Tina Spokes, Curtis Harmon, Barbara Kimball-Goodman, Alton Allen.
     - The PMAC recommends recruiting a pediatrician and a dietician.
     - The PMAC assigned the pharmacist consultants to research articles relating doses of psychotropic medications to weight gain to help determine if weight gain may be dose related. Findings are to be forwarded to Dr. Siegel.
   - Potential Changes to Pharmacy Contract: there has been a request to cut the pharmacy contract by 5%. It was noted that the Governor has the authority to require an additional 5% cut.
     - The PMAC discussed the cost benefit risk and the medical legal risk of reducing the pharmacy consulting contract.
     - The PMAC supports maintaining the pharmacy contract as is and this recommendation will be communicated to DCF by Dr. Williams.
   - Medicaid Update: The preauthorization requirement for those instances when a once a day medication is prescribed to be administered more than once a day was discussed. Dr. Williams will draft a letter regarding the issues PMAC has identified surrounding this requirement.
     - Robert Zavoski and Mark Schaefer of DSS will be invited to a subsequent PMAC meeting to discuss this and other medication related issues.
5. **Update by PMAC Annual Psychopharmacology Conference Sub-Committee**
   - Funding Opportunities: Beth Muller led the discussion and provided an update on the activities of this sub-committee:
     - Clifford Beers Issue: The “2nd Trauma Conference on Prevention and Early Intervention” will be held at Foxwoods conflicting with our proposed conference date. There was a discussion of the pros and cons of combining our conference with theirs.
       1. Noted that there is a parallel to other activities at the conference.
       2. Foxwoods may provide a reduced rate for hotel accommodations and food would be included.
       3. Various programming formats were discussed regarding targeting pediatrics vs. psychiatrists.
       4. PMAC would NOT be able to provide CME through Connecticut Valley Hospital.
   - Dr. Van Wattum will assist with coordinating so a timely decision can be made.

6. **Adverse Drug Reaction Reporting (ADR)**
   - A quantitative and qualitative analysis of ADR’s reported between October 2007 and September 2009 was distributed, reviewed, and discussed in detail.
   - The PMAC focused discussion on the 2 ADRs that may have been preventable (Geodon and Abilify).
   - PMAC recommends obtaining ADR reports from RVHCY and incorporating them into the analysis. Dr. Veivia will be responsible for coordinating with RVHCY.
   - PMAC assigned the pharmacy consultants to determine if Moban is associated with less weight gain than the atypical antipsychotics.
   - Formulary: the status of Intuniv (guanfacine extended release formulation) was discussed: PMAC voted to add this medication to the approved drug list, the drug use guidelines and dosing guidelines.
   - The accuracy of the DCF Web Site was discussed. Dr. Williams will determine who is responsible for updating the site.

7. **Review of 4 Articles**: distributed, reviewed and discussed in detail:
   - Article 1 reviewed and discussion led by Dr. Williams.
     - The method and cost of bringing a new drug to market was discussed.
     - Phases I-IV discussed.
     - Noted that it takes about 10 years from initial discovery to market at a cost of about $1.5 billion.
     - Differences of this process between countries discussed.
The challenges of working with pediatric patients noted and discussed. Suggested that the benefit to risk ratio should be higher in the pediatric setting.

Best Pharmaceuticals for Children Act discussed.

- Article 2: Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Specialty Clinic; reviewed and discussion led by Aurele Kamm.

- Article 3: Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder; reviewed and discussion led by Chris Malinowski.
  - Methods were discussed re how valid this study is.
  - Side effects were discussed.

- Article 4: Methylphenidate Combined with Aripiprazole in Children and Adolescents with Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder: a Randomized Crossover Trial; reviewed and discussion let by Curtis Harmon.
  - Some dosing issues were discussed.

8. Follow-up on Medication Booklet: Defer

9. OTHER:
   - CCMC Issue: The following case was described: 35month old went to the ED for head banging and fits. This patient also had a presumptive UTI. Patient was prescribed Risperidone 0.5mg po bid.
   - Issues include:
     - There seems to have been a misdiagnosis in that the child was thought to have a behavioral problem vs. a medical problem.
     - The form sent to CMCU was missing vital information including weight.
     - The next follow-up date was scheduled for February 2010.
   - There was discussion as to what might be implemented to prevent this type of situation the future. Some type of case review services was discussed.

10. Adjournment: Dr. Williams adjourned the Committee at 3:00PM.

Respectfully Submitted:
David S. Aresco